Condensed Consolidated Statements of Cash Flow - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
OPERATING ACTIVITIES
Net loss for the period	$ (130,000,000)	$ (14,886,000)	$ (145,874,000)	$ (26,875,000)
Items not involving cash:
Deferred Income taxes	(64,864,000)	0	(64,864,000)	0
Depreciation of property and equipment	252,000	147,000	469,000	267,000
Unrealized foreign exchange (gains) losses	51,000	2,639,000	(2,956,000)	(4,418,000)
Change in fair value of warrant liability	(168,000)	(2,024,000)	(329,000)	(801,000)
Change in fair value of contingent consideration	252,000	0	496,000	0
Impairment of intangible assets	156,324,000	0	156,324,000	0
Net change in non-cash operating items:
Accounts receivable	(116,000)	(1,738,000)	552,000	(4,624,000)
Accrued revenue	0	1,304,000	0	178,000
Investment tax credits receivable	98,000	0	98,000	0
Prepaid expenses and other assets	(573,000)	(519,000)	(847,000)	(298,000)
Accounts payable and accrued liabilities	42,000	(7,351,000)	(1,074,000)	(5,343,000)
Deferred revenue	(213,000)	334,000	(370,000)	(957,000)
Net cash used in operating activities	(16,804,000)	(16,671,000)	(28,351,000)	(35,641,000)
INVESTING ACTIVITIES
Disposition (acquisition) of short and long-term investments, net	(84,439,000)	(9,944,000)	(97,745,000)	27,419,000
Cash acquired through acquisition	0	0	0	324,000
Acquisition of property and equipment	(954,000)	(383,000)	(1,230,000)	(524,000)
Net cash provided by (used) in investing activities	(85,393,000)	(10,327,000)	(98,975,000)	27,219,000
FINANCING ACTIVITIES
Proceeds from issuance of common shares, net of issuance costs	0	2,000	0	142,177,000
Issuance of common shares pursuant to exercise of options	1,000	939,000	116,000	1,559,000
Issuance of common shares pursuant to exercise of warrants	445,000	19,000	445,000	44,000
Net cash provided by financing activities	446,000	960,000	561,000	143,780,000
Effect of foreign exchange rate changes on cash and cash equivalents	(51,000)	967,000	2,956,000	(340,000)
(Decrease) Increase in cash and cash equivalents	(101,802,000)	(25,071,000)	(123,809,000)	135,018,000
Cash and cash equivalents, beginning of period	144,772,000	232,276,000	166,779,000	72,187,000
Cash and cash equivalents, end of period	42,970,000	207,205,000	42,970,000	207,205,000
Non-cash transactions:
Investment tax credit received	0	25,000	0	25,000
Acquisition of Arbutus Inc. excluding cash acquired	0	0	0	381,618,000
Research, development, collaborations and contracts expenses
Items not involving cash:
Stock-based compensation	2,519,000	1,377,000	5,466,000	2,705,000
General and administrative expenses
Items not involving cash:
Stock-based compensation	$ 19,592,000	$ 4,046,000	$ 24,558,000	$ 4,525,000